Literature DB >> 1763539

The effect of renal failure on hepatic drug clearance.

M A Touchette1, R L Slaughter.   

Abstract

It is known that loss of renal function decreases the hepatic clearance of some drugs, but the mechanisms by which this occurs are unclear. Knowledge of which drugs display reduced hepatic metabolism may be important for appropriate dosing of these drugs in uremic patients. Although no firm conclusions can be made regarding common pharmacokinetic and metabolic characteristics of drugs that display decreased hepatic metabolism in renal failure, certain observations deserve consideration. It appears that drugs metabolized by oxidation, conjugation, or both may be predisposed to decreased hepatic clearance in renal failure. Drugs that undergo oxidation by the P-450IID6 isozyme may be more likely to exhibit inhibition whereas those metabolized by the P-450IIIA4 isozyme may be spared. Future studies designed to clarify the mechanisms of decreased hepatic clearance in renal failure should take into account the multiplicity of P-450 enzymes for drugs that are oxidatively metabolized. The phenomenon of reduced hepatic drug clearance in uremia should be considered when evaluating the influence of renal failure on drug disposition.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1763539     DOI: 10.1177/106002809102501111

Source DB:  PubMed          Journal:  DICP        ISSN: 1042-9611


  23 in total

1.  Low responsiveness to clopidogrel increases risk among CKD patients undergoing coronary intervention.

Authors:  Patrik Htun; Suzanne Fateh-Moghadam; Christian Bischofs; Winston Banya; Karin Müller; Boris Bigalke; Konstantinos Stellos; Andreas E May; Marcus Flather; Meinrad Gawaz; Tobias Geisler
Journal:  J Am Soc Nephrol       Date:  2011-01-27       Impact factor: 10.121

2.  Downregulation of hepatic acetylation of drugs in chronic renal failure.

Authors:  Emilie Simard; Judith Naud; Josée Michaud; Francois A Leblond; Alain Bonnardeaux; Chantal Guillemette; Edith Sim; Vincent Pichette
Journal:  J Am Soc Nephrol       Date:  2008-04-16       Impact factor: 10.121

3.  Successful treatment of a hemodialyzed patient with pure red cell aplasia associated with epoetin beta pegol therapy with cyclosporine.

Authors:  Keiji Hirai; Susumu Ookawara; Haruhisa Miyazawa; Kiyonori Ito; Yuichiro Ueda; Yoshio Kaku; Taro Hoshino; Shun-Ichi Kimura; Izumi Yoshida; Sachiko Kakuta; Yoshiyuki Morishita; Kaoru Tabei
Journal:  CEN Case Rep       Date:  2015-09-15

4.  The pharmacokinetics of pioglitazone in patients with impaired renal function.

Authors:  Klemens Budde; Hans-Hellmut Neumayer; Lutz Fritsche; Wladyslaw Sulowicz; Tomasz Stompôr; David Eckland
Journal:  Br J Clin Pharmacol       Date:  2003-04       Impact factor: 4.335

5.  Pharmacokinetics and safety of letermovir, a novel anti-human cytomegalovirus drug, in patients with renal impairment.

Authors:  Dirk Kropeit; Jürgen Scheuenpflug; Katharina Erb-Zohar; Atef Halabi; Hans-Peter Stobernack; Ellen G J Hulskotte; Arne van Schanke; Holger Zimmermann; Helga Rübsamen-Schaeff
Journal:  Br J Clin Pharmacol       Date:  2017-05-05       Impact factor: 4.335

6.  Effect of Renal Impairment on the Pharmacokinetics of Pradigastat, a Novel Diacylglycerol Acyltransferase1 (DGAT1) Inhibitor.

Authors:  Sachiko Mita; Dan Meyers; Parasar Pal; TsuHan Lin; Tapan Majumdar; Sam Rebello; Gangadhar Sunkara; Jin Chen
Journal:  Clin Pharmacokinet       Date:  2015-07       Impact factor: 6.447

7.  Sources of Interindividual Variability.

Authors:  Yvonne S Lin; Kenneth E Thummel; Brice D Thompson; Rheem A Totah; Christi W Cho
Journal:  Methods Mol Biol       Date:  2021

8.  Physiologically Based Pharmacokinetic Model of the CYP2D6 Probe Atomoxetine: Extrapolation to Special Populations and Drug-Drug Interactions.

Authors:  Weize Huang; Mariko Nakano; Jennifer Sager; Isabelle Ragueneau-Majlessi; Nina Isoherranen
Journal:  Drug Metab Dispos       Date:  2017-08-31       Impact factor: 3.922

9.  Hepatic clearance, but not gut availability, of erythromycin is altered in patients with end-stage renal disease.

Authors:  H Sun; L A Frassetto; Y Huang; L Z Benet
Journal:  Clin Pharmacol Ther       Date:  2010-01-20       Impact factor: 6.875

Review 10.  The effect of chronic renal failure on drug metabolism and transport.

Authors:  Albert W Dreisbach; Juan J L Lertora
Journal:  Expert Opin Drug Metab Toxicol       Date:  2008-08       Impact factor: 4.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.